ArticleExperimental hematology & oncology2023

A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.

Jie Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.